Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 137

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 137
---
 healthcare and lifestyle decisions. As such, users of our tests may have a greater sensitivity to errors than users of some other types of products and services. We must maintain top service standards and other quality controls. Past or future performance or accuracy defects, incomplete or improper process controls, excessively slow turnaround times, unanticipated uses of our tests or mishandling of samples or test results (whether by us, patients, healthcare providers, courier delivery services, or others) can lead to adverse outcomes for our customers and interruptions to our services. These events could lead to voluntary or legally mandated safety alerts relating to our tests or our laboratory facilities and could result in the removal of our products and services from the market or the suspension of our laboratories’ operations. Insufficient quality controls and any resulting negative outcomes could result in significant costs and litigation, as well as negative publicity that could reduce demand for our tests and payers’ willingness to cover our tests. Even if we maintain adequate controls and procedures, damaging and costly errors may occur. The occurrence of any of these events could have an adverse impact on our business, financial condition, results of operations and growth prospects. Our future AI Agents business will significantly depend upon third -party infrastructures, including language models and other AI technologies, which are subject to developing regulatory frameworks. Our future AI Agents, which will be designed to provide personalized health guidance based on genomic, microbiome, clinical, and lifestyle data, present inherent risks. As these AI Agents will interact directly with customers, there is a potential for errors or inaccuracies in recommendations due to software limitations, algorithmic biases, or integration issues. Such inaccuracies could lead to adverse health outcomes, customer dissatisfaction, or legal claims, affecting our reputation and operations. While we will implement rigorous validation processes, the dynamic nature of AI technologies means unforeseen issues could arise, leading to potential liabilities. Our development and deployment of AI Agents would rely on third -partyinfrastructures, including large language models (LLMs) and other AI technologies which are continuously evolving. While these technologies enhance our ability to provide personalized health management services, they introduce risks related to the accuracy, reliability, and security of AI -generatedrecommendations. AI Agents may produce incorrect, incomplete, or inappropriate responses, 47 potentially affecting customer health outcomes. These risks are inherent to current AI technologies and may persist or evolve as technology advances. Additionally, regulatory frameworks for AI in healthcare are still emerging, and future legal requirements could impact our operations, requiring modifications to our AI systems. To mitigate these risks, we plan to